In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Annals

Antimicrobial Therapeutics Reviews

Edited by Edited by Karen Bush (Indiana University, Bloomington, Indiana)
Antimicrobial Therapeutics Reviews

Published: December 2011

Volume 1241

The second installment of this Annals series presents scholarly reviews on several key areas in the field of antimicrobial therapeutics.
Learn More

This second installment of Antimicrobial Therapeutics Reviews presents scholarly reviews on several key areas in the field of antimicrobial therapeutics, including several papers on issues relating to antibiotics that target the ribosome. Topics covered include plasmid-encoded resistance determinants for agents that bind the ribosome, new compound classes targeting the ribosome, sequence-specific action of antibiotics binding the ribosome, smFRET approaches to determine MOA of antibiotics binding to the ribosome, new approaches for treating Staphylococcus biofilm infections, and the history of tetracyclins. The volume also features reviews dealing with drug development, such as pleuromutilin discovery and development challenges and an update on newer oxazolidinones such as torezolid and radezolid, and a review on regulatory hurdles for new antibiotics.